4-Star Stocks Poised to Pop: Accuray
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, robotic radiosurgery specialist Accuray (NAS: ARAY) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Accuray's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Sunnyvale, Calif. (1990)|
|Market Cap||$299 million|
|Trailing-12-Month Revenue||$285 million|
|Management||CEO Dr. Euan Thomson (since 2002)|
CFO Derek Bertocci (since 2009)
|Return on Equity (Average, Past 3 Years)||(7.8%)|
|Cash/Debt||$140 million / $76.6 million|
|Competitors||Varian Medical Systems (NYS: VAR)|
Sources: S&P Capital IQ and Motley Fool CAPS.
Earlier this week, robertshrestha listed several of Accuray's positives: "Nice growth prospects as uses for CyberKnife system expands, solid balance sheet, beaten-down stock price. What's not to like?!"
Over the next five years, in fact, Accuray is expected to grow its bottom line at a brisk rate of 20% annually. That's faster than main rival Varian Medical (13%), as well much larger medical device plays like Medtronic (NYS: MDT) (7%) and Zimmer Holdings (NYS: ZMH) (9%).
CAPS member NJ7 elaborates on the bull case:
Accuray's niche is robotic laser surgery. This has low toxicity and a dramatic impact on cancer treatment (though no treatment is perfect). [Accuray] is both first mover and top dog in this particular area because I believe its CyberKnife to be the best available technology as reflected by widespread adaptation. Its acquisition of TomoTherapy allowed it to expand into related fields. Varian Medical is the main competitor with differing products providing similar methods of treatment. But the essential premise I base my investment thesis on is that hospitals are not nearly saturated with either technology. There are hundreds of hospitals with these technologies, eventually there could be thousands in the USA alone.
What do you think about Accuray, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Medtronic and Zimmer. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.